OBJECTIVE: In the antenatal late preterm steroids (ALPS) trial betamethasone significantly decreased short-term neonatal respiratory morbidity but increased the risk of neonataloglycemia, diagnosed only categorically (72 hours was rare and similar in both groups, nine (2.4%, betamethasone) and four (1.9%, placebo, p = 0.18). CONCLUSION: In this cohort, hypoglycemia was transient and most received no treatment, with a quicker resolution in the betamethasone group. Prolonged hypoglycemia was uncommon irrespective of steroid exposure. KEY POINTS: . Hypoglycemia was transient and approximately two-thirds received no treatment.. . Neonates in the ALPS trial who received betamethasone had a shorter time to resolution than those with hypoglycemia in the placebo group.. . Prolonged hypoglycemia occurred in approximately 2 out of 100 late preterm newborns, irrespective of antenatal steroid exposure..
Reference Type
Journal Article
Periodical Full
American Journal of Perinatology
Publication Year
2021
Publication Date
May 27
Place of Publication
United States
ISSN/ISBN
1098-8785
Accession Number
PMID: 34044454
Document Object Index
10.1055/s-0041-1729561 [doi]
PMID
34044454